2H-Pyran-4-carboxamide, 4-amino-N-[(1S,2E)-4-(2,3-dihydro-1H-indol-1-yl)-1-(2-methylpropyl)-4-oxo-2-buten-1-yl]tetrahydro- manufacturers
|
| | 2H-Pyran-4-carboxamide, 4-amino-N-[(1S,2E)-4-(2,3-dihydro-1H-indol-1-yl)-1-(2-methylpropyl)-4-oxo-2-buten-1-yl]tetrahydro- Basic information |
| | 2H-Pyran-4-carboxamide, 4-amino-N-[(1S,2E)-4-(2,3-dihydro-1H-indol-1-yl)-1-(2-methylpropyl)-4-oxo-2-buten-1-yl]tetrahydro- Chemical Properties |
| Boiling point | 587.2±50.0 °C(Predicted) | | density | 1.158±0.06 g/cm3(Predicted) | | pka | 15.70±0.20(Predicted) |
| | 2H-Pyran-4-carboxamide, 4-amino-N-[(1S,2E)-4-(2,3-dihydro-1H-indol-1-yl)-1-(2-methylpropyl)-4-oxo-2-buten-1-yl]tetrahydro- Usage And Synthesis |
| Uses | Propyl-GSK2793660 is a potent cathepsin C inhibitor that holds potential for treating cystic fibrosis, noncystic fibrosis bronchiectasis, ANCA-associated vasculitis, and bronchiectasis. | | References | [1] Discovery of Second Generation Reversible Covalent DPP1 Inhibitors Leading to an Oxazepane Amidoacetonitrile Based Clinical Candidate (AZD7986) |
| | 2H-Pyran-4-carboxamide, 4-amino-N-[(1S,2E)-4-(2,3-dihydro-1H-indol-1-yl)-1-(2-methylpropyl)-4-oxo-2-buten-1-yl]tetrahydro- Preparation Products And Raw materials |
|